Patents by Inventor Sam D. Sanderson
Sam D. Sanderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10945962Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.Type: GrantFiled: December 4, 2018Date of Patent: March 16, 2021Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Joseph A. Vetro, Sam D. Sanderson
-
Publication number: 20200172587Abstract: Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.Type: ApplicationFiled: June 12, 2018Publication date: June 4, 2020Inventors: Sam D. Sanderson, Edward Leroy Morgan
-
Patent number: 10363282Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.Type: GrantFiled: January 12, 2018Date of Patent: July 30, 2019Assignees: Board of Regents of The University of Nebraska, San Diego State University Research FoundationInventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
-
Publication number: 20190083408Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.Type: ApplicationFiled: December 4, 2018Publication date: March 21, 2019Inventors: Joseph A. Vetro, Sam D. Sanderson
-
Patent number: 10220002Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.Type: GrantFiled: November 30, 2012Date of Patent: March 5, 2019Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Joseph A. Vetro, Sam D. Sanderson
-
Publication number: 20180140659Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
-
Publication number: 20180066018Abstract: Conformationally-stable peptide analogs of the response selective C5a agonist EP67 having the formula Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO:1), wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine. The conformationally-stable peptides selectively bind and activate APCs without directly engaging/binding C5a receptor-bearing cells involved in pro-inflammatory activities of natural C5a. Compositions and methods of using the peptide analogs are also described.Type: ApplicationFiled: March 11, 2016Publication date: March 8, 2018Inventors: Sam D. Sanderson, Jonathan Vennerstrom
-
Patent number: 9895411Abstract: Materials and methods for treating and preventing an infection or disease, and for directly killing microorganisms, using carboxy-terminal C5a analogs, are provided.Type: GrantFiled: June 29, 2011Date of Patent: February 20, 2018Assignees: SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
-
Publication number: 20150297668Abstract: Materials and methods for treating and preventing an infection or disease, and for directly killing microorganisms, using carboxy-terminal C5a analogs, are provided.Type: ApplicationFiled: June 29, 2011Publication date: October 22, 2015Applicants: SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION, BOARD PF REGENTS OF THE UNIVERSITY OF NEBRASKAInventor: Sam D. Sanderson
-
Publication number: 20150218516Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: ApplicationFiled: March 9, 2015Publication date: August 6, 2015Inventors: Stefano R. Tarantolo, Anthony A. Floreani, Ralph J. Hauke, John D. Jackson, Sam D. Sanderson, Art J. Heires, Sandra Gunselman
-
Publication number: 20140314839Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventors: Joseph A. Vetro, Sam D. Sanderson
-
Publication number: 20080286228Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: ApplicationFiled: April 6, 2007Publication date: November 20, 2008Inventors: Stefano R. Tarantolo, Anthony A. Floreani, Ralph J. Hauke, John D. Jackson, Sam D. Sanderson, Art J. Heires, Sandra Gunselman
-
Patent number: 7358087Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen. In particular, these molecular adjuvants are employed in compositions designed to deliver the specific immunogen to antigen presenting cells and simultaneously deliver signals to those cells that produce the desired immune response. Methods are also disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: September 17, 2001Date of Patent: April 15, 2008Assignee: Board of Regents of The University of NebraskaInventors: Sam D. Sanderson, Michael A. Hollingsworth, Richard A. Tempero
-
Patent number: 7291336Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand functionally linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens, etc. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: May 28, 2004Date of Patent: November 6, 2007Assignee: Board of Regents of the University of NebraskaInventor: Sam D. Sanderson
-
Patent number: 7063847Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: May 5, 2000Date of Patent: June 20, 2006Assignee: The Board of Regents of the University of NebraskaInventors: Sam D. Sanderson, Michael A. Hollingworth, Richard M. Tempero
-
Patent number: 6821517Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand functionally linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens, etc. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: April 17, 1998Date of Patent: November 23, 2004Assignee: The Board of Regents of the University of NebraskaInventors: Sam D. Sanderson, Michael A. Hollingsworth, Richard A. Tempero
-
Patent number: 6465614Abstract: High-affinity response-selective C-terminal analogs of C5a anaphylatoxin are provided. Whereas natural C5a has considerable flexibility in the C-terminal region, the analogs of the invention possess a backbone conformation which is constrained at the C-terminus to a &bgr;-turn. The stabilized &bgr;-turn confers a marked increase in potency of the analogs; the particular &bgr;-turn motif further confers the capability to selectively elicit certain biological responses associated with C5a. Exemplary compounds of the invention are decapeptide analogs of the formula: A1-Ser-Phe-Lys-A2-A3-A4-A5-A6-A7, with the constrained &bgr;-turn being localized in the region of A4-A7.Type: GrantFiled: July 21, 1999Date of Patent: October 15, 2002Assignee: The Board of Regents of the University of NebraskaInventors: Sam D. Sanderson, Simon A. Sherman, Leonid Kirnarsky, Stephen M. Taylor
-
Publication number: 20020091234Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen. In particular, these molecular adjuvants are employed in compositions designed to deliver the specific immunogen to antigen presenting cells and simultaneously deliver signals to those cells that produce the desired immune response. Methods are also disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: ApplicationFiled: September 17, 2001Publication date: July 11, 2002Applicant: The Board of Regents of the University of NebraskaInventors: Sam D. Sanderson, Michael A. Hollingsworth, Richard A. Tempero
-
Patent number: 5942599Abstract: High-affinity response-selective C-terminal analogs of C5a anaphylatoxin are provided. Whereas natural C5a has considerable flexibility in the C-terminal region, the analogs of the invention possess a backbone conformation which is constrained at the C-terminus to a .beta.-turn. The stabilized .beta.-turn confers a marked increase in in potency of the analogs; the particular .beta.-turn motif further confers the capability to selectively elicit certain biological responses associated with C5a. Exemplary compounds of the invention are decapeptide analogs of the formula: A1-Ser-Phe-Lys-A2-A3-A4-A5-A6-A7, with the constrained .beta.-turn being localized in the region of A4-A7.Type: GrantFiled: December 4, 1997Date of Patent: August 24, 1999Assignees: Board of Regents of the University of Nebraska, The University of QueenslandInventors: Sam D. Sanderson, Simon A. Sherman, Leonid Kirnarsky, Stephen M. Taylor
-
Patent number: 5696230Abstract: High-affinity response-selective C-terminal analogs of C5a anaphylatoxin are provided. Whereas natural C5a has considerable flexibility in the C-terminal region, the analogs of the invention possess a backbone conformation which is constrained at the C-terminus to a .beta.-turn. The stabilized .beta.-turn confers a marked increase in in potency of the analogs; the particular .beta.-turn motif further confers the capability to selectively elicit certain biological responses associated with C5a. Exemplary compounds of the invention are decapeptide analogs of the formula: A1-Ser-Phe-Lys-A2-A3-A4-A5-A6-A7, with the constrained .beta.-turn being localized in the region of A4-A7.Type: GrantFiled: August 31, 1994Date of Patent: December 9, 1997Assignees: The Board of Regents of the University of Nebraska, The University of QueenslandInventors: Sam D. Sanderson, Simon A. Sherman, Leonid Kirnarsky, Stephen M. Taylor